Endocyte inc (ECYT)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net loss

-55,064

-43,887

-41,269

5,459

-18,032

-17,291

-40,531

-20,092

-17,005

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

922

919

886

857

674

358

262

260

231

Stock-based compensation

4,170

9,322

6,920

8,025

6,059

3,022

1,960

523

381

Acquired in-process research and development

16,539

0

0

-

-

-

-

-

-

Loss (gain) on disposal of property and equipment

-106

0

-10

6

-1

-6

-20

0

-3

Loss on extinguishment of debt

-

-

-

-

-

-992

0

-144

-

Accretion of bond premium

-161

395

1,310

1,615

1,246

961

343

-3

-17

Net realized foreign currency translation loss

0

0

-51

0

0

-

-

-

-

Non cash interest expense

-

-

-

-

-

73

646

160

210

Change in operating assets and liabilities:
Receivables

-1

-191

-856

-5,490

2,508

1,409

0

-

-

Decrease in fair value on preferred stock warrants

-

-

-

-

-

-

-

237

74

Extinguishment of liability

-

-

-

-

-

-

-

18

-

Receivables

-

-

-

-

-

-

-

0

-

Prepaid expenses and other assets

-915

517

96

-2,711

-2,016

1,287

-932

2,323

-269

Accounts payable

-1,025

-252

-60

-3,700

-386

524

943

-118

493

Accrued wages, benefits and other liabilities

-13

-771

-777

-2,923

1,337

3,483

838

922

109

Deferred revenue

-50

-50

-50

-59,746

-41,488

99,757

0

0

-

Net cash used in operating activities

-33,658

-34,650

-32,218

-42,205

-51,080

89,191

-34,584

-20,745

-15,396

Investing activities
Purchases of property and equipment

82

713

341

1,501

827

1,862

234

200

155

Proceeds from disposal of property and equipment

15

0

0

10

0

0

-

-

-

Purchases of investments

106,724

139,932

86,281

149,370

125,026

265,203

236,930

12,295

35,496

Purchase of acquired in-process research and development

12,770

0

0

-

-

-

-

-

-

Proceeds from sale and maturities of investments

134,930

190,765

88,114

82,302

195,146

163,671

169,853

27,507

33,785

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

26,602

Proceeds from borrowings, net of issuance costs

-

-

-

-

-

-

-

14,857

-

Proceeds from issuance of subordinated convertible notes, net of issuance costs

-

-

-

-

-

-

3,590

8,040

-

Principal payments on borrowings

-

-

-

-

-

13,544

2,708

9,137

5,518

Proceeds from third public offering, net of issuance costs

-

-

-

-

-

0

-

-

-

Proceeds from second public offering, net of issuance costs

-

-

-

-

-

-

66,734

0

-

Net cash provided by (used in) investing activities

15,367

50,118

1,490

-68,560

69,292

-103,395

-67,311

15,010

-1,866

Stock repurchase

94

164

57

3

0

0

-

-

-

Proceeds from exercise of warrant to purchase common stock

4,556

0

0

-

-

-

-

-

-

Proceeds from issuance of common stock in connection with equity offering

-

-

-

101,904

0

-

-

-

-

Proceeds from the exercise of stock options

1,087

261

379

1,290

644

391

595

147

-

Proceeds from stock purchases under employee stock purchase plan

72

231

305

299

0

0

78,167

0

-

Net cash provided by financing activities

5,621

328

627

103,491

644

-13,152

146,381

13,907

21,083

Effect of exchange rate

0

0

-1

-38

-6

0

-5

0

-

Net increase (decrease) in cash and cash equivalents

-12,669

15,796

-30,101

-7,313

18,850

-27,355

44,479

8,173

3,820